← 返回

脂联素与维生素 D 同 TIL(肿瘤浸润淋巴细胞)及 III 期结肠癌生存的关联

英文原题:Association of Adiponectin and Vitamin D With Tumor Infiltrating Lymphocytes and Survival in Stage III Colon Cancer.

查看英文原题

Association of Adiponectin and Vitamin D With Tumor Infiltrating Lymphocytes and Survival in Stage III Colon Cancer.

PubMed 2021/07/23(内容时间) JNCI Cancer Spectr Q2 · IF 4.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

循环脂联素水平较低与结肠癌中 TIL 密度显著增加相关,表明抗肿瘤免疫反应增强。与 TIL 不同,脂联素和 25(OH)D 均不是独立预后因素。

研究思路结论见上方概要

脂肪细胞来源的脂联素可能在宿主对癌症的炎症反应中发挥作用。我们研究了血浆脂联素与结肠癌中TIL(肿瘤浸润淋巴细胞)(TILs)密度以及与维生素D、临床病理特征和患者生存之间的关系。

采用放射免疫分析法对600例接受FOLFOX方案辅助化疗的III期结肠癌患者(NCCTG N0147 [Alliance])的血浆脂联素和25-羟基维生素D [25(OH)D]进行了分析。在组织病理学切片中测定了TIL密度。通过多变量Cox回归校正潜在混杂因素(即体重指数、种族、TILs和N分期)后,评估了其与无病生存期(DFS)、复发时间和总生存期的关联。所有统计学检验均为双侧。

我们发现,与TIL密度低的肿瘤相比,TIL密度高的肿瘤中脂联素水平有统计学显著降低,但25(OH)D没有(中位数 = 6845 vs 8984 ng/mL;P = .04)。在肥胖(体重指数 >30 kg/m 2)与非肥胖患者(中位数 = 6608 vs 12 351 ng/mL;P < .001)、男性与女性(中位数 = 8185 vs 11 567 ng/mL;P < .001)、黑人 vs 白人 vs 亚裔(中位数 = 6412 vs 8847 vs 7858 ng/mL;P < .03)以及淋巴结转移较少者(N1 vs N2:中位数 = 7768 vs 9253 ng/mL;P = .01)中,也观察到脂联素有统计学显著降低。291例(48.5%)患者检测到25(OH)D不足(<30 ng/mL)。在多变量分析中,在调整潜在混杂因素的模型里,脂联素和25(OH)D均与DFS、总生存期或复发时间无统计学显著差异相关。我们发现TILs与预后有统计学显著关联,但在脂联素与TILs对DFS的关联中未观察到这种交互作用。

展开英文摘要原文

Adipocyte-derived adiponectin may play a role in the host inflammatory response to cancer. We examined the association of plasma adiponectin with the density of tumor-infiltrating lymphocytes (TILs) in colon cancers and with vitamin D, clinicopathological features, and patient survival.

Plasma adiponectin and 25-hydroxyvitamin D [25(OH)D] were analyzed by radioimmunoassay in 600 patients with stage III colon cancer who received FOLFOX-based adjuvant chemotherapy (NCCTG N0147 [Alliance]). TIL densities were determined in histopathological sections. Associations with disease-free survival (DFS), time to recurrence, and overall survival were evaluated by multivariable Cox regression adjusting for potential confounders (ie, body mass index, race, TILs, and N stage). All statistical tests were 2-sided.

We found a statistically significant reduction in adiponectin, but not 25(OH)D, levels in tumors with high vs low TIL densities (median = 6845 vs 8984 ng/mL; P = .04). A statistically significant reduction in adiponectin was also observed in obese (body mass index >30 kg/m 2 ) vs nonobese patients (median = 6608 vs 12 351 ng/mL; P < .001), in men vs women (median = 8185 vs 11 567 ng/mL; P < .001), in Blacks vs Whites or Asians (median = 6412 vs 8847 vs 7858 ng/mL; P < .03), and in those with fewer lymph node metastases (N1 vs N2: median = 7768 vs 9253 ng/mL; P = .01). Insufficiency of 25(OH)D (<30 ng/mL) was detected in 291 (48.5%) patients. In multivariable analyses, neither adiponectin nor 25(OH)D were associated with a statistically significant difference in DFS, overall survival , or time to recurrence in models adjusted for potential confounders. We found a statistically significant association of TILs with prognosis, yet no such interaction was observed for the association of adiponectin with TILs for DFS.

Lower circulating adiponectin levels were associated with a statistically significant increase in TIL densities in colon cancers, indicating an enhanced antitumor immune response. In contrast to TILs, neither adiponectin nor 25(OH)D was independently prognostic.

论文信息

作者
Sinicrope FA、Shi Q、Smyrk TC、Goldberg RM、Cohen SJ、Gill S、Kahlenberg MS、Nair S
单位
Division of Oncology and Mayo Clinic Comprehensive Cancer Center, Rochester, MN, USA.United States
文献类型
随机对照试验 · 美国 NIH 资助研究 · 非美国政府资助研究
期刊
JNCI cancer spectrum2021 Oct
原文标识
PubMed 34485815 · DOI 10.1093/jncics/pkab070